Tedopi® in Phase 3 clinical trial in advanced cell lung cancer

OSE-172 (Effi-DEM), a new generation checkpoint inhibitor, developed in immuno-oncology

FR104 and OSE-127 (Effi-7) are targeted for autoimmune diseases and transplantation